Full-Time

Associate Director/Director

Alliance Management, AI Discovery

Updated on 8/1/2026

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$155k - $240k/yr

Remote in USA + 1 more

More locations: San Diego, CA, USA

Remote

Remote within the US; onsite work at the San Diego headquarters is preferred, with hybrid models available.

Category
Business & Strategy (1)
Required Skills
Machine Learning
Medicinal Chemistry

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific discipline, engineering, business, or related field is required.
  • At least 10 years of experience for the Associate Director level or 12 years for the Director level in alliance management, scientific program management, project management, or scientific operations within biotechnology, pharmaceuticals, or artificial intelligence-driven life sciences is required.
  • Experience managing complex scientific collaborations and strategic partnerships is required.
  • Understanding of drug discovery, machine learning, or computational research environments is required.
  • The role requires organizational, communication, and stakeholder management skills.
  • The role requires the ability to influence across multidisciplinary teams without direct authority.
Responsibilities
  • Serve as the primary alliance manager for artificial intelligence-enabled drug discovery collaborations and strategic external partnerships.
  • Build and maintain trusted relationships with pharmaceutical, biotechnology, and technology partners across scientific, operational, and executive levels.
  • Lead collaboration governance, including Joint Steering Committees, scientific working groups, executive reviews, agendas, action tracking, and decision documentation.
  • Partner with Discovery Machine Learning, Computational Chemistry, Biology, Medicinal Chemistry, Software Engineering, Legal, Business Development, and other cross-functional teams to align collaboration objectives, milestones, and deliverables.
  • Develop and maintain integrated collaboration plans covering timelines, governance milestones, partner commitments, contractual obligations, budgets, and partnership metrics.
  • Coordinate cross-functional execution across multiple partnered programs by identifying risks, tracking dependencies, facilitating issue resolution, and ensuring operational excellence.
  • Translate complex artificial intelligence, machine learning, computational chemistry, and scientific concepts into clear, actionable updates for external collaborators while aligning technical teams with partner objectives.
  • Develop sufficient technical understanding of the company's artificial intelligence discovery platform and computational workflows to represent collaborative programs, anticipate partner questions, and facilitate scientific discussions.
  • Partner with Legal and Business Development to support collaboration agreements, governance structures, data sharing, publications, and strategic partnership activities.
  • Prepare executive updates, partnership reports, and presentations while contributing to the evaluation and launch of new strategic collaborations.
  • Help establish and continuously improve alliance management processes, governance standards, and best practices as the collaboration portfolio grows.
Desired Qualifications
  • An advanced degree, specifically a Master of Science or Doctor of Philosophy, is preferred.
  • Experience supporting artificial intelligence, machine learning, computational biology, computational chemistry, or artificial intelligence-enabled drug discovery organizations is preferred.
  • Experience working with pharmaceutical, biotechnology, academic, or technology collaborations is preferred.
  • Familiarity with collaboration agreements, governance structures, and cross-company research programs is preferred.
  • Alliance Management (ASAP), Project Management Professional, or similar certification is preferred.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda collaboration on February 9, 2026, offers up to $1.7B in milestones.
  • Over $100M oversubscribed funding in November 2025 from Sequoia and Regeneron.
  • Pipeline advances IAM1363 to Phase 1b with positive ESMO safety data.

What critics are saying

  • Exscientia’s EXS-21546 captures HER2 market with Phase 1 data in 6-12 months.
  • Insilico’s ISM1363 HER2 degrader enters Phase 1, outperforming IAM1363 in 12-18 months.
  • IAM1363 Phase 1 fails safety due to EGFR toxicity, halting in 3-9 months.

What makes Iambic Therapeutics unique

  • NeuralPLexer outperforms in predicting protein-ligand complexes per Nature Machine Intelligence.
  • IAM1363 shows 1000-fold HER2 selectivity over EGFR with CNS penetrance in Phase 1.
  • Weekly design-make-test cycles via Enchant and automated labs accelerate discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
intelligence360
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

entArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.